Brain metastases, which are both particularly refractory to systemic anticancer therapies, and a manifestation of advanced disease, are an urgent unmet need especially in HER2+ breast cancer given heavy dependence on antibody-based therapies which may have more limited CNS penetration than other anticancer drug classes. The gene discussed is ERBB2; the disease is breast cancer.